The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

A population based trial has shown that allopurinol use dose escalation and achieving target uric acid levels (with allopurinol), was not associated with increased mortality in patients with gout and concurrent CKD

Mayo Clinic Proceedings reports the results of a retrospective, cross-sectional of patients with HFE hemochromatosis showing that advanced hepatic fibrosis is primarily seen in those with arthritis due to HFE hemochromatosis. 

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.

The PsA Expert panelists included:

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout.

A study of men with gout from the US Veteran’s Health Administration (VHA) shows that excess mortality in gout could be attributed to comorbidities.

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Whether patients with ankylosing spondylitis (AS) would improve substantially with tumor necrosis factor (TNF) inhibitor therapy was predicted with moderate to high accuracy based only on a standard lab test and two measures of disease activity, researchers reported from a modeling study.

A phase II trial in patients with active giant cell arteritis shows that mavrilimumab, a monoclonal antibody against granulocyte-macrophage colony-stimulating factor [GM-CSF]) is capable of inducing clinical remission.

The risk of developing axial spondyloarthritis (axSpA) if you’re a first-degree relative (FDRs) of an ankylosing spondylitis (AS) patient has been deflined by a 35 year follow-up study showing that if you are a FDR of axSpA you may be at higher risk of acute anterior uveitis (AAU).

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Concerns about the long-term safety of hydroxychloroquine (HCQ) often results in dose reduction or drug discontinuation; yet a current study shows that, for those in remission, HCQ taper/discontinuation resulted in a significantly higher rate of SLE flares.

MMWR has reported the results of the National Football Leagues (NFL) change in SARS-CoV-2 testing program that went into effect in December 2021, at the height of the Omicron variant surge, showing that among those with asymptomatic infection, only half were PCR test negative and could return to

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.

Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.

The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.